The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study

SIMPLE SUMMARY: Programmed death 1 (PD1)/programmed death ligand-1 (PD-L1) inhibitor is the standard therapy for advanced microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal cancers. However, the suitable therapy after the progression of anti-PD1/PD-L1 for MSI/dMMR gas...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Mifen, Wang, Zhenghang, Liu, Zimin, Liu, Ning, Fang, Weijia, Zhang, Hangyu, Jin, Xuan, Li, Jiayi, Zhao, Weifeng, Qu, Huajun, Song, Fanghua, Chang, Zhiwei, Li, Yi, Tang, Yong, Xu, Chunlei, Zhang, Xiaotian, Wang, Xicheng, Peng, Zhi, Cai, Jinping, Li, Jian, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601260/
https://www.ncbi.nlm.nih.gov/pubmed/36291942
http://dx.doi.org/10.3390/cancers14205158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601260/
https://www.ncbi.nlm.nih.gov/pubmed/36291942
http://dx.doi.org/10.3390/cancers14205158

Ejemplares similares